Literature DB >> 15063127

HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses.

Erik Rollman1, Lisen Arnheim, Brian Collier, Daniel Oberg, Håkan Hall, Jonas Klingström, Joakim Dillner, Diana V Pastrana, Chris B Buck, Jorma Hinkula, Britta Wahren, Stefan Schwartz.   

Abstract

Introduction of point mutations in the 5' end of the human papillomavirus type 16 (HPV-16) L1 gene specifically inactivates negative regulatory RNA processing elements. DNA vaccination of C57Bl/6 mice with the mutated L1 gene resulted in improved immunogenicity for both neutralizing antibodies as well as for broad cellular immune responses. Previous reports on the activation of L1 by codon optimization may be explained by inactivation of the regulatory RNA elements. The modified HPV-16 L1 DNA that induced anti-HPV-16 immunity may be seen as a complementary approach to protein subunit immunization against papillomavirus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063127     DOI: 10.1016/j.virol.2004.02.002

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Maturation of papillomavirus capsids.

Authors:  Christopher B Buck; Cynthia D Thompson; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

2.  Development of chimeric candidate vaccine against HPV18: a proof of concept.

Authors:  Mohammed Wahiduzzaman; Chandresh Sharma; Bindu Dey; Neerja Bhatla; Neeta Singh
Journal:  Immunol Res       Date:  2015-06       Impact factor: 2.829

3.  A splicing enhancer in the E4 coding region of human papillomavirus type 16 is required for early mRNA splicing and polyadenylation as well as inhibition of premature late gene expression.

Authors:  Margaret Rush; Xiaomin Zhao; Stefan Schwartz
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  A 57-nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFip1, CstF-64, hnRNP C1/C2, and polypyrimidine tract binding protein.

Authors:  Xiaomin Zhao; Daniel Oberg; Margaret Rush; Joanna Fay; Helen Lambkin; Stefan Schwartz
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 5.  Regulation of human papillomavirus gene expression by splicing and polyadenylation.

Authors:  Cecilia Johansson; Stefan Schwartz
Journal:  Nat Rev Microbiol       Date:  2013-03-11       Impact factor: 60.633

6.  Identification of an hnRNP A1-dependent splicing silencer in the human papillomavirus type 16 L1 coding region that prevents premature expression of the late L1 gene.

Authors:  Xiaomin Zhao; Margaret Rush; Stefan Schwartz
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Inhibition of HPV-16 L1 expression from L1 cDNAs correlates with the presence of hnRNP A1 binding sites in the L1 coding region.

Authors:  Xiaomin Zhao; Stefan Schwartz
Journal:  Virus Genes       Date:  2007-11-27       Impact factor: 2.332

8.  Suppression of HPV-16 late L1 5'-splice site SD3632 by binding of hnRNP D proteins and hnRNP A2/B1 to upstream AUAGUA RNA motifs.

Authors:  Xiaoze Li; Cecilia Johansson; Jacob Glahder; Ann-Kristin Mossberg; Stefan Schwartz
Journal:  Nucleic Acids Res       Date:  2013-09-05       Impact factor: 16.971

9.  Optimizing a Human Papillomavirus Type 16 L1-Based Chimaeric Gene for Expression in Plants.

Authors:  Inga I Hitzeroth; Aleyo Chabeda; Mark P Whitehead; Marcus Graf; Edward P Rybicki
Journal:  Front Bioeng Biotechnol       Date:  2018-07-16

10.  Brucella abortus RB51 lipopolysaccharide influence as an adjuvant on the therapeutic efficacy of HPV16 L1 and HPV16 E7 DNA vaccines.

Authors:  Masoumeh Shirmohammadi; Hoorieh Soleimanjahi; Zahra Kianmehr; Hesam Karimi; Susan Kaboudanian Ardestani
Journal:  Iran J Basic Med Sci       Date:  2021-01       Impact factor: 2.699

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.